Dyne Therapeutics, Inc (DYN)

$8.81

+0.21

(+2.44%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Dyne Therapeutics, Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 120.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.1% return, outperforming this stock by 225.1%

Performance

  • $8.35
    $8.81
    $8.81
    downward going graph

    5.22%

    Downside

    Day's Volatility :5.22%

    Upside

    0.0%

    downward going graph
  • $8.04
    $15.60
    $8.81
    downward going graph

    8.74%

    Downside

    52 Weeks Volatility :48.46%

    Upside

    43.53%

    downward going graph

Returns

PeriodDyne Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
-19.17%
-1.1%
0.0%
6 Months
-22.73%
1.6%
0.9%
1 Year
-35.63%
4.2%
3.1%
3 Years
-60.0%
24.2%
17.1%

Highlights

Market Capitalization
549.8M
Book Value
$3.39
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.38
PEG Ratio
0.19
Wall Street Target Price
29.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-41.13%
Return On Equity TTM
-76.65%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-193.0M
Diluted Eps TTM
-3.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.47
EPS Estimate Next Year
-3.12
EPS Estimate Current Quarter
-0.81
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Dyne Therapeutics, Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 234.85%

Current $8.81
Target $29.50

Technicals Summary

Sell

Neutral

Buy

Dyne Therapeutics, Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
-25.86%
-22.73%
-35.63%
-60.0%
-64.02%
Moderna, Inc.
Moderna, Inc.
-12.64%
-32.32%
-18.59%
40.95%
434.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.2%
0.68%
18.02%
45.57%
106.06%
Novo Nordisk A/s
Novo Nordisk A/s
-2.18%
18.08%
84.58%
165.14%
289.05%
Seagen, Inc.
Seagen, Inc.
3.05%
4.69%
54.33%
11.57%
175.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.55%
11.62%
19.58%
30.6%
81.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
NA
NA
0.19
-3.47
-0.77
-0.41
0.0
3.39
Moderna, Inc.
Moderna, Inc.
34.67
34.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.3
43.3
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.94
26.94
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dyne Therapeutics, Inc
Dyne Therapeutics, Inc
Buy
$549.8M
-64.02%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.3B
434.62%
34.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
106.06%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$410.6B
289.05%
43.3
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
175.61%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
81.41%
26.94
35.4%

Institutional Holdings

  • Mpm Asset Management, LLC

    8.11%

  • BlackRock Inc

    5.44%

  • Citadel Advisors Llc

    4.43%

  • Deep Track Capital, LP

    4.10%

  • Vanguard Group Inc

    3.91%

  • Wasatch Advisors Inc.

    3.70%

Corporate Announcements

  • Dyne Therapeutics, Inc Earnings

    Dyne Therapeutics, Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.

Organization
Dyne Therapeutics, Inc
Employees
134
CEO
Mr. Joshua T. Brumm
Industry
Commercial Services

Discover More

FAQs